Iradimed Net Income From Continuing Ops from 2010 to 2026
| IRMD Stock | USD 97.98 1.02 1.03% |
Net Income From Continuing Ops | First Reported 2012-12-31 | Previous Quarter 5.8 M | Current Value 5.6 M | Quarterly Volatility 1.8 M |
Check Iradimed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iradimed's main balance sheet or income statement drivers, such as Depreciation And Amortization of 621.7 K, Interest Expense of 702.6 K or Selling General Administrative of 9.9 M, as well as many indicators such as Price To Sales Ratio of 9.68, Dividend Yield of 0.0283 or PTB Ratio of 10.18. Iradimed financial statements analysis is a perfect complement when working with Iradimed Valuation or Volatility modules.
Iradimed | Net Income From Continuing Ops | Build AI portfolio with Iradimed Stock |
Analyzing Iradimed's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing Iradimed's current valuation and future prospects.
Latest Iradimed's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Iradimed Co over the last few years. It is Iradimed's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iradimed's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Iradimed Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 8,579,841 | |
| Geometric Mean | 5,218,358 | |
| Coefficient Of Variation | 88.84 | |
| Mean Deviation | 6,191,752 | |
| Median | 7,214,545 | |
| Standard Deviation | 7,622,443 | |
| Sample Variance | 58.1T | |
| Range | 22.7M | |
| R-Value | 0.86 | |
| Mean Square Error | 16T | |
| R-Squared | 0.74 | |
| Slope | 1,299,749 | |
| Total Sum of Squares | 929.6T |
Iradimed Net Income From Continuing Ops History
About Iradimed Financial Statements
Iradimed stakeholders use historical fundamental indicators, such as Iradimed's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Iradimed investors may analyze each financial statement separately, they are all interrelated. For example, changes in Iradimed's assets and liabilities are reflected in the revenues and expenses on Iradimed's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Iradimed Co. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 22.1 M | 23.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:Check out the analysis of Iradimed Correlation against competitors. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Will Health Care Equipment & Supplies sector continue expanding? Could Iradimed diversify its offerings? Factors like these will boost the valuation of Iradimed. Market participants price Iradimed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Iradimed data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.079 | Dividend Share 0.68 | Earnings Share 1.65 | Revenue Per Share | Quarterly Revenue Growth 0.157 |
Iradimed's market price often diverges from its book value, the accounting figure shown on Iradimed's balance sheet. Smart investors calculate Iradimed's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Iradimed's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.